BR112012018771A2 - ''método para dianosticar insuficência cardíaca em um sujeito'' - Google Patents

''método para dianosticar insuficência cardíaca em um sujeito''

Info

Publication number
BR112012018771A2
BR112012018771A2 BR112012018771A BR112012018771A BR112012018771A2 BR 112012018771 A2 BR112012018771 A2 BR 112012018771A2 BR 112012018771 A BR112012018771 A BR 112012018771A BR 112012018771 A BR112012018771 A BR 112012018771A BR 112012018771 A2 BR112012018771 A2 BR 112012018771A2
Authority
BR
Brazil
Prior art keywords
subject
heart failure
diagnosing heart
diagnosing
failure
Prior art date
Application number
BR112012018771A
Other languages
English (en)
Inventor
Leibold Edgar
A Katus Hugo
Fuhrmann Jens
Wolf Johanna
Kastler Jürgen
Busch Kristina
Frey Norberth
Reszka Regina
Weis Tanja
Original Assignee
Metanomics Gmbh
Univ Heidelberg Ruprecht Karls
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Metanomics Gmbh, Univ Heidelberg Ruprecht Karls filed Critical Metanomics Gmbh
Publication of BR112012018771A2 publication Critical patent/BR112012018771A2/pt

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/92—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving lipids, e.g. cholesterol, lipoproteins, or their receptors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
    • A61B5/00—Measuring for diagnostic purposes; Identification of persons
    • A61B5/02—Detecting, measuring or recording pulse, heart rate, blood pressure or blood flow; Combined pulse/heart-rate/blood pressure determination; Evaluating a cardiovascular condition not otherwise provided for, e.g. using combinations of techniques provided for in this group with electrocardiography or electroauscultation; Heart catheters for measuring blood pressure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
    • A61B5/00—Measuring for diagnostic purposes; Identification of persons
    • A61B5/145—Measuring characteristics of blood in vivo, e.g. gas concentration, pH value; Measuring characteristics of body fluids or tissues, e.g. interstitial fluid, cerebral tissue
    • A61B5/14546—Measuring characteristics of blood in vivo, e.g. gas concentration, pH value; Measuring characteristics of body fluids or tissues, e.g. interstitial fluid, cerebral tissue for measuring analytes not otherwise provided for, e.g. ions, cytochromes
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/64—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving ketones
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2570/00—Omics, e.g. proteomics, glycomics or lipidomics; Methods of analysis focusing on the entire complement of classes of biological molecules or subsets thereof, i.e. focusing on proteomes, glycomes or lipidomes
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/32—Cardiovascular disorders
    • G01N2800/325—Heart failure or cardiac arrest, e.g. cardiomyopathy, congestive heart failure
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
BR112012018771A 2010-01-29 2011-01-28 ''método para dianosticar insuficência cardíaca em um sujeito'' BR112012018771A2 (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US29936010P 2010-01-29 2010-01-29
EP10000915 2010-01-29
PCT/EP2011/051208 WO2011092285A2 (en) 2010-01-29 2011-01-28 Means and methods for diagnosing heart failure in a subject

Publications (1)

Publication Number Publication Date
BR112012018771A2 true BR112012018771A2 (pt) 2017-06-20

Family

ID=44319898

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112012018771A BR112012018771A2 (pt) 2010-01-29 2011-01-28 ''método para dianosticar insuficência cardíaca em um sujeito''

Country Status (8)

Country Link
US (2) US9285378B2 (pt)
EP (2) EP3502707A1 (pt)
JP (3) JP5813665B2 (pt)
AU (2) AU2011209431B2 (pt)
BR (1) BR112012018771A2 (pt)
CA (2) CA3012137A1 (pt)
IL (1) IL220842B (pt)
WO (1) WO2011092285A2 (pt)

Families Citing this family (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3502707A1 (en) * 2010-01-29 2019-06-26 metanomics GmbH Means and methods for diagnosing heart failure in a subject
NO2385374T3 (pt) * 2010-05-05 2014-06-07
EP2580596B1 (en) 2010-06-10 2015-02-25 Metanomics Health GmbH Methods to diagnose liver diseases
CA2841915A1 (en) * 2011-07-28 2013-01-31 Metanomics Gmbh Means and methods for diagnosing and monitoring heart failure in a subject
EP2822457A4 (en) * 2012-03-09 2015-11-11 Basf Se MEANS AND METHODS FOR ASSESSING HYPERTHYROIDISM
EP2667197B1 (en) * 2012-05-25 2015-09-16 Zora Biosciences OY Sensitive efficacy and specificity biomarkers for proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibition
DE102012209059B4 (de) 2012-05-30 2024-05-02 Siemens Healthineers Ag Verfahren und Vorrichtung zur Bestimmung einer zeitlichen Änderung eines Biomarkers in einem Untersuchungsgebiet
ES2686542T3 (es) 2012-10-18 2018-10-18 Metanomics Gmbh Medios y procedimientos para determinar una cantidad normalizada de aclaramiento de un biomarcador de enfermedad metabólica en una muestra
US20160209433A1 (en) * 2013-08-30 2016-07-21 Metanomics Gmbh Means and methods for diagnosing heart failure in a subject
US20150090010A1 (en) * 2013-09-27 2015-04-02 Chang Gung University Method for diagnosing heart failure
CA2925691A1 (en) * 2013-10-01 2015-04-09 Ruprecht-Karls-Univeristat Heidelberg S100 based treatment of cardiac power failure
US9347960B2 (en) * 2014-06-16 2016-05-24 Zora Biosciences, Oy Ceramides and their use in diagnosing CVD
CA2954870A1 (en) * 2014-07-28 2016-02-04 Metanomics Gmbh Means and methods for diagnosing heart failure on the basis of cholesterol parameters, sphingomyelins and/or triacylglycerols
WO2016034600A1 (en) * 2014-09-01 2016-03-10 Metanomics Gmbh Means and methods for diagnosing heart failure in a subject
EP3213085B2 (en) * 2014-10-29 2022-09-28 Roche Diagnostics GmbH Biomarkers for risk prediction of progression of chronic heart failure and mortality
WO2016187620A2 (en) 2015-05-21 2016-11-24 The Regents Of The University Of California Anti-cancer compounds
CN108885219A (zh) 2016-02-04 2018-11-23 梅坦诺米克斯有限公司 用于在受试者中鉴别心力衰竭和肺部疾病的装置和方法
DK3430098T3 (da) 2016-03-18 2021-12-20 Solvay Vandbaseret antikorrosionsbelægningssammensætning
IL263917B (en) 2016-06-24 2022-07-01 Univ California Pthalazine derivatives as parp1, parp2 and/or tubulin suppressors for use in cancer therapy
TWI805565B (zh) * 2017-01-27 2023-06-21 日商斯德武利姆股份有限公司 心肌病、陳舊性心肌梗塞及慢性心臟衰竭的治療藥物
EP3579919A4 (en) * 2017-02-10 2020-12-09 The Regents of the University of California THERAPEUTIC INTERVENTION PROCESSES, DEVICES AND SYSTEMS
EP3718561A4 (en) 2017-12-01 2021-07-21 Stemrim Inc. Therapy for inflammatory bowel disease
CN111830142A (zh) * 2019-04-23 2020-10-27 北京市心肺血管疾病研究所 神经酰胺在制备用于评估心力衰竭患者发生不良事件风险的试剂盒中的应用
CN114460201B (zh) * 2022-02-10 2023-04-28 北京市心肺血管疾病研究所 一组区分缺血性心脏病（ihd）与缺血性心力衰竭（ihf）的诊断标志物

Family Cites Families (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4540884A (en) 1982-12-29 1985-09-10 Finnigan Corporation Method of mass analyzing a sample by use of a quadrupole ion trap
DE3922873A1 (de) 1989-04-25 1990-10-31 Boehringer Mannheim Gmbh Spezifische antikoerper gegen troponin t, ihre herstellung und verwendung in einem reagenz zur bestimmung von hermuskelnekrosen
US5397894A (en) 1993-05-28 1995-03-14 Varian Associates, Inc. Method of high mass resolution scanning of an ion trap mass spectrometer
DE19815128A1 (de) 1997-04-03 1998-10-08 Franz Wolfgang M Dr Transgenes Tiermodell für humane Kardiomyopathien
CA2293718A1 (en) * 1997-06-10 1998-12-17 Medlyte Diagnostics, Inc. Methods for early detection of heart disease
DE19915485A1 (de) 1999-04-07 2000-10-19 Hugo A Katus Therapie der Herzinsuffizienz
WO2002075302A1 (en) * 2001-03-15 2002-09-26 Xiao Yong Fu Method for therapeutically treating a clinically recognized form of cardiopathology in a living mammal
WO2003073464A1 (de) 2002-02-28 2003-09-04 Metanomics Gmbh & Co. Kgaa Massenspektrometrisches verfahren zur analyse von substanzgemischen
ES2288718T3 (es) 2004-07-07 2008-01-16 F. Hoffmann-La Roche Ag Panel de multiples marcadores para la diabetes de tipo 1 y de tipo 2.
WO2007144467A1 (en) * 2006-06-12 2007-12-21 Zora Biosciences Oy Diagnostic method for myopathy
US8321154B2 (en) * 2007-03-26 2012-11-27 Bg Medicine, Inc. Methods for detecting coronary artery disease
EP2153236A1 (en) * 2007-06-07 2010-02-17 INSERM (Institut National de la Santé et de la Recherche Médicale) Method for assessing the risk of a cardiovascular disease and for diagnosing dyslipidemia
US20100267062A1 (en) * 2007-09-26 2010-10-21 Norbert Frey Osteopontin as Novel Prognostic Biomarker for Heart Failure
JP2011501133A (ja) * 2007-10-10 2011-01-06 ビージー メディシン， インコーポレイテッド 心血管または脳血管主要有害事象を検出するための方法
EP3059592A1 (en) 2008-05-28 2016-08-24 Basf Se Methods for assessing liver toxicity
WO2009153139A2 (en) 2008-05-28 2009-12-23 Basf Se Means and methods for assessing increased peroxisomal proliferation
DE112009001245T5 (de) 2008-05-28 2012-03-15 Basf Se Mittel und Verfahren für die Beurteilung der Leberenzyminduktion
EP2313773A1 (en) 2008-07-15 2011-04-27 Metanomics Health GmbH Means and methods diagnosing gastric bypass and conditions related thereto
NZ593221A (en) * 2008-11-06 2012-10-26 Musc Found For Res Dev Detecting and monitoring left ventricular hypertrophy and congestive heart failure by profiling biomarkers
WO2010139711A1 (en) 2009-06-04 2010-12-09 Metanomics Health Gmbh Means and methods for diagnosing prostate carcinomas
CN102472744B (zh) 2009-08-13 2015-11-25 巴斯夫欧洲公司 诊断甲状腺疾病的手段和方法
WO2011054702A1 (en) * 2009-10-28 2011-05-12 Umit (Private Universität Für Gesundheitswissenschaften, Medizinische Informatik Und Technik) Identification of biomarkers
EP2944964B1 (en) * 2009-11-27 2018-01-10 Baker IDI Heart and Diabetes Institute Holdings Ltd Lipid biomarkers for stable and unstable heart disease
AU2010326737A1 (en) 2009-12-01 2012-06-07 Metanomics Health Gmbh Means and methods for diagnosing multiple sclerosis
EP3502707A1 (en) * 2010-01-29 2019-06-26 metanomics GmbH Means and methods for diagnosing heart failure in a subject
NO2385374T3 (pt) * 2010-05-05 2014-06-07
EP3355057A3 (en) 2010-06-01 2018-12-12 Metanomics Health GmbH Means and methods for diagnosing pancreatic cancer in a subject
EP2580596B1 (en) 2010-06-10 2015-02-25 Metanomics Health GmbH Methods to diagnose liver diseases
WO2012166798A2 (en) * 2011-06-01 2012-12-06 Wake Forest University Health Sciences Systems and apparatus for indicating risk of coronary stenosis
CA2841915A1 (en) * 2011-07-28 2013-01-31 Metanomics Gmbh Means and methods for diagnosing and monitoring heart failure in a subject
US20160209433A1 (en) * 2013-08-30 2016-07-21 Metanomics Gmbh Means and methods for diagnosing heart failure in a subject
CA2954870A1 (en) * 2014-07-28 2016-02-04 Metanomics Gmbh Means and methods for diagnosing heart failure on the basis of cholesterol parameters, sphingomyelins and/or triacylglycerols
WO2016034600A1 (en) * 2014-09-01 2016-03-10 Metanomics Gmbh Means and methods for diagnosing heart failure in a subject

Also Published As

Publication number Publication date
JP2017167158A (ja) 2017-09-21
US20120286157A1 (en) 2012-11-15
JP6181712B2 (ja) 2017-08-16
US10393762B2 (en) 2019-08-27
AU2011209431B2 (en) 2016-09-08
AU2016266098B2 (en) 2018-12-06
CA3012137A1 (en) 2011-08-04
US20160154012A1 (en) 2016-06-02
EP2529235B1 (en) 2019-03-06
JP6479096B2 (ja) 2019-03-06
US9285378B2 (en) 2016-03-15
CA2787297C (en) 2018-09-04
WO2011092285A2 (en) 2011-08-04
IL220842B (en) 2018-12-31
JP5813665B2 (ja) 2015-11-17
WO2011092285A3 (en) 2012-05-03
EP2529235A2 (en) 2012-12-05
AU2016266098A1 (en) 2016-12-22
AU2011209431A1 (en) 2012-08-02
CA2787297A1 (en) 2011-08-04
EP3502707A1 (en) 2019-06-26
JP2013518271A (ja) 2013-05-20
JP2016001183A (ja) 2016-01-07

Similar Documents

Publication Publication Date Title
BR112012018771A2 (pt) ''método para dianosticar insuficência cardíaca em um sujeito''
NO2020037I1 (no) alpelisib eller et farmasøytisk akseptabelt salt derav
NO2019024I1 (no) Brigatinib eller et farmasøytisk akseptabelt salt derav
NO2017057I1 (no) pibrentasvir eller et farmasøytisk akseptabelt salt derav
NO2019008I1 (no) Allopurinol/lesinurad eller et farmasøytisk aksepterbart salt eller salter derav
NO2017059I1 (no) ribosiklib eller et farmasøytisk akseptabelt salt derav
SMT201600289B (it) Nuove immunoadesine ctla4-ig
IL230492A0 (en) Means and methods for diagnosing and monitoring heart failure in the subject
NO2015012I2 (no) Ombitasvir, eller et farmasøytisk akseptabelt salt derav
EP2739974A4 (en) METHOD AND COMPOSITIONS FOR HEART ERROR MONITORING
FR2960520B1 (fr) Aeronef comprenant un moteur de train
BR112014002174A2 (pt) estrutura de válvula cardíaca, estrutura de válvula cardíaca em múltiplas-lâminas e método para fabricar uma estrutura de válvula cardíaca
BR112012023255A2 (pt) método para preparar uma estrutura fotoabsorvente contendo calcogênio e dispositivo fotovoltaico
ZA201205219B (en) Method for diagnosing the stsate of health of a battery
FI20115576A0 (fi) Menetelmä Alzheimerin taudin diagnoimiseksi
BR112014016292A2 (pt) montagem de fixação occipito-cervical e método para construir a mesma
FR2979574B1 (fr) Procede de fabrication d'une structure comprenant une peau et des raidisseurs
DK2547252T3 (da) Elektrokardiografisk overvågningssystem
EP2646822A4 (en) METHODS AND COMPOSITIONS FOR DIAGNOSIS AND PREDICTION OF THE RISK OF CARDIAC INSUFFICIENCY
DK2828668T3 (da) Hydroxy-sphingomyelin 22:1 som biomarkør for sund aldring
DE102010054926A8 (de) Lagereinheit für einen Turbolader
FI20105386A (fi) Nesterengaspumppu ja menetelmä nesterengaspumpun käyttämiseksi
BR112013007040A2 (pt) "método para preparar um composto e composto"
ZA201309124B (en) Compositions and methods for diagnosing and monitoring hyperthyroidism in a feline
HK1170577A1 (en) Increasing database availability during fault recovery

Legal Events

Date Code Title Description
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B07A Application suspended after technical examination (opinion) [chapter 7.1 patent gazette]
B09B Patent application refused [chapter 9.2 patent gazette]
B09B Patent application refused [chapter 9.2 patent gazette]

Free format text: MANTIDO O INDEFERIMENTO UMA VEZ QUE NAO FOI APRESENTADO RECURSO DENTRO DO PRAZO LEGAL